BC-LI-0186 [CAS 695207-56-8]

BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM) . BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated MTOR mutants and the growth of rapamycin-resistant cancer cells. BC-LI-0186 is a promising agent for lung cancer research[1][2].

[695207-56-8]

C22H27N3O4S

429.53

O=S(C1=CC=C(N2N(C)C(C)=C(C(C)C)C2=O)C=C1)(NCCOC3=CC=CC=C3)=O

Aminoacyl-tRNA Synthetase

10mM

99.2

DMSO : 125 mg/mL (ultrasonic)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H315, H319

H315, H319